Live from the NIH registry
Studies recruiting near Muskegon right now
Top 25 of 60 recruiting studies, sorted by proximity — each links to its official registry page
Collection and Storage of Tissue and Blood Samples From Patients With Cancer
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
N/A
Observational 5,000 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: National Cancer Institute LAO
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Intestinal Neoplasms, Gastrointestinal Neoplasms
Phase 3
Interventional 800 participants sought
The Cancer & Hematology Centers — Norton Shores, Michigan (4.1 mi)
· Sponsor: Pfizer
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Phase 3
Interventional 247 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: National Cancer Institute (NCI)
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma
Phase 2, Phase 3
Interventional 992 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: National Cancer Institute (NCI)
Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
Miscellaneous Neoplasm, Nos, Non-Neoplastic Condition, Nos
N/A
Interventional 535 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma
Phase 3
Interventional 360 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: National Cancer Institute (NCI)
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Multiple conditions
Phase 2
Interventional 150 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: National Cancer Institute (NCI)
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma
Phase 2
Interventional 396 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: SWOG Cancer Research Network
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
N/A
Interventional 9,500 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: NRG Oncology
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma
Phase 2
Interventional 189 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma
Phase 3
Interventional 880 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: NRG Oncology
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Ovarian Carcinoma
N/A
Interventional 1,956 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: NRG Oncology
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Stage I Breast Cancer
Phase 3
Interventional 1,670 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: NRG Oncology
Cost Communication and Financial Navigation in Cancer Patients (COSTCOM)
Malignant Solid Neoplasm
N/A
Interventional 760 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Cardiotoxicity, HER2/Neu Positive
Phase 3
Interventional 491 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: SWOG Cancer Research Network
Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors
Hodgkin Lymphoma, Non-Hodgkin Lymphoma
N/A
Observational 2,000 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Breast Carcinoma, Colorectal Carcinoma
N/A
Observational 2,000 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: Wake Forest University Health Sciences
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
Smoldering Plasma Cell Myeloma
Phase 3
Interventional 288 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Plasma Cell Myeloma
Phase 3
Interventional 510 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: SWOG Cancer Research Network
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
Phase 3
Interventional 1,875 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: National Cancer Institute (NCI)
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Phase 3
Interventional 60 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: Children's Oncology Group
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Intracranial Meningioma, Recurrent Meningioma
Phase 2
Interventional 124 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: Alliance for Clinical Trials in Oncology
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
Cutaneous Melanoma
Phase 3
Interventional 428 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: ECOG-ACRIN Cancer Research Group
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
Recurrent T Acute Lymphoblastic Leukemia, Refractory T Acute Lymphoblastic Leukemia
Phase 1, Phase 2
Interventional 67 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: SWOG Cancer Research Network
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma (RCC)
Phase 3
Interventional 1,040 participants sought
Trinity Health Muskegon Hospital — Muskegon, Michigan (0.6 mi)
· Sponsor: Alliance for Clinical Trials in Oncology